Navigation Links
Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
Date:4/30/2013

ed experience in building visionary companies and we are proud and excited to welcome him to our board," said Stephane Bancel , founding president and CEO of Moderna. "Under his leadership, Genzyme became known for its steadfast commitment to patients, and for constantly pushing new boundaries in order to bring biomedical innovation to those who were not well served by traditional approaches. This perspective will be enormously helpful to Moderna as we work to unlock the vast potential of messenger RNA therapeutics™."

About Henri A. Termeer

Henri A. Termeer served as chairman, president and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care.

Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, Board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School and on the Board of the Biotechnology Industry Organization (BIO). He also serves on the Boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. In 2008, he was appointed to Massachusetts Governor Deval Patrick 's Council of Economic Advisors and he is a co-chair of the Leadership Council of the Massachusett
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. David Hooper Joins Evolution Marketing Research as Senior Director, Research
2. Full Service CRO DAaCRO Joins Salimetrics Center of Excellence Program
3. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
4. Revolutionary new device joins world of smart electronics
5. Jerry Adams Joins VIC Technology Venture Development Board of Directors
6. Noted Atherosclerosis Researcher Joins AtheroNova Team
7. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
8. Leo Gingras Joins Nutraceutical Innovations, LLC Board of Directors
9. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
10. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
11. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... Fla. , Aug. 27, 2015 The ... that a patient,s eyes—and life—were saved by doctors at ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Care Center at Seton Medical Center in ... successful treatment used a breakthrough approach, pioneered by Dr. ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... SUNNYVALE, Calif., June 1 Pharmacyclics, Inc. (Nasdaq: ... on Form S-3 with the Securities and Exchange Commission (the ... The rights offering will be made through the distribution of ... stock, par value $0.0001 per share, at a subscription price ...
... ... Generation nonfood Biofuel crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech ... all set to provide the most authoritative Knowledge platform for Development ... Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Pharmacyclics Files Registration Statement for Rights Offering 2Pharmacyclics Files Registration Statement for Rights Offering 3Pharmacyclics Files Registration Statement for Rights Offering 4Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... Gerton Lab has provided new evidence to clarify the ... required for proper kinetochore function, which plays a critical ... in yeast cells, was published in the most recent ... centromeric nucleosome acts as a guide for the position ...
... have discovered a huge number of new species of ... amid the harsh conditions of the Australian outback. ... new species of invertebrates, which include various insects, small ... led by Professor Andy Austin (University of Adelaide), ...
... a plant in Erie County that has never been recorded ... with the aid of a Mercyhurst College professor on the ... is known to exist in northern U.S. states and in ... until this discovery. WPC scientists found a small population of ...
Cached Biology News:Gerton Lab determines the composition of centromeric chromatin 2Researchers go underground to reveal 850 new species 2Erie County home to plant never before recorded in Pa. 2
... S-7 stirrers deliver accurate and ... fluids away from internal components. ... controls which allow users to ... tops feature a chemical resistant, ...
... loxP-cm-loxP cassette is designed to ... The prokaryotic promoter gb2 driving ... a slightly modified version of the ... efficiency than the generally used Tn5 ...
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: